Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 8/20 | 0.80 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.62 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5307753 | 1.00 | SLC6A3 (0.80) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL6574453 | 1.00 | SLC6A3 (0.80) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL6576682 | 1.00 | SLC6A3 (0.80) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL3000484 | 1.00 | SLC6A3 (0.80) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL7347413 | 1.00 | SLC6A3 (0.80) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL5731609 | 1.00 | SLC6A3 (0.80) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL5731604 | 1.00 | SLC6A3 (0.80) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL6574450 | 1.00 | SLC6A3 (0.80) | SLC6A3SLC6A2SLC6A4 | |
| SCHEMBL5731428 | 0.89 | SLC6A3 (0.76) | SLC6A3 | |
| SCHEMBL5731247 | 0.87 | SLC6A3 (0.82) | SLC6A3SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1513529-B1 | TRIPLE MONOAMINE REUPTAKE INHIBITORS FOR THE TREATMENT OF CHRONIC PAIN | NEUROSEARCH AS (DK) | 2011-12-14 | — | — | EP | claimed |
| US-20100178342-A1 | Solid Pharmaceutical Preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-15 | — | — | US | claimed |
| EP-1453511-B1 | TROPANE DERIVATIVES HAVING DOPAMINE REUPTAKE INHIBITOR ACTIVITY FOR THE TREATMENT OF ISCHEMIC DISEASES | NEUROSEARCH AS (DK) | 2006-11-15 | — | — | EP | claimed |
| US-20050239824-A1 | Triple monoamine reuptake inhibitors for the treatment of chronic pain | NEUROSEARCH A/S (DK) | 2005-10-27 | — | — | US | claimed |
| US-20050203124-A1 | Compounds for the sustained reduction of body weight | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2005-09-15 | — | — | US | claimed |
| US-20050182089-A1 | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an N-methyl-D-aspartate (NMDA) receptors antagonist | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-18 | — | — | US | claimed |
| US-20050182090-A1 | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2005-08-18 | — | — | US | claimed |
| EP-1513529-A1 | TRIPLE MONOAMINE REUPTAKE INHIBITORS FOR THE TREATMENT OF CHRONIC PAIN | NEUROSEARCH A/S (DK) | 2005-03-16 | — | — | EP | claimed |
| US-20050020621-A1 | Tropane derivatives having dopamine reuptake inhibitor activity for the treatment of ischemic diseases | SANIONA A/S (DK) | 2005-01-27 | — | — | US | claimed |
| EP-1453511-A1 | TROPANE DERIVATIVES HAVING DOPAMINE REUPTAKE INHIBITOR ACTIVITY FOR THE TREATMENT OF ISCHEMIC DISEASES | NEUROSEARCH A/S (DK) | 2004-09-08 | — | — | EP | claimed |
| WO-2003101453-A1 | TRIPLE MONOAMINE REUPTAKE INHIBITORS FOR THE TREATMENT OF CHRONIC PAIN | NEUROSEARCH A/S (DK) | 2003-12-11 | — | — | WO | claimed |
| WO-2003045388-A1 | TROPANE DERIVATIVES HAVING DOPAMINE REUPTAKE INHIBITOR ACTIVITY FOR THE TREATMENT OF ISCHEMIC DISEASES | NEUROSEARCH A/S (DK) | 2003-06-05 | — | — | WO | claimed |
| EP-1513529-B1 | TRIPLE MONOAMINE REUPTAKE INHIBITORS FOR THE TREATMENT OF CHRONIC PAIN | NEUROSEARCH AS (DK) | 2011-12-14 | — | — | EP | disclosed |
| US-20100210626-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITOR AND AN ACETYLCHOLINESTERASE INHIBITOR | FRIEDL THOMAS | 2010-08-19 | — | — | US | disclosed |
| US-20100178342-A1 | Solid Pharmaceutical Preparation | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-07-15 | — | — | US | disclosed |
| US-7459464-B2 | Triple monoamine reuptake inhibitors for the treatment of chronic pain | NEUROSEARCH A/S (DK) | 2008-12-02 | — | — | US | disclosed |
| US-5736556-A | PARKINSON*S DISEASE; ANTIDEPRESSANTS; ANTIOBESITY; ANTINARCOLEPSY; DRUG ABRUSE | NEUROSEARCH A/S (DK) | 1998-04-07 | — | — | US | disclosed |
| WO-1997030997-A1 | TROPANE-DERIVATIVES, THEIR PREPARATION AND USE | NEUROSEARCH A/S (DK) | 1997-08-28 | — | — | WO | disclosed |
| EP-0756596-A1 | TROPANE-2-ALDOXIME DERIVATIVES AS NEUROTRANSMITTER REUPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 1997-02-05 | — | — | EP | disclosed |
| WO-1995028401-A1 | TROPANE-2-ALDOXINE DERIVATIVES AS NEUROTRANSMITTER REUPTAKE INHIBITORS | NEUROSEARCH A/S (DK) | 1995-10-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182089-A1 | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and an N-methyl-D-aspartate (NMDA) receptors antagonist | SLC18A2, SLC6A2, SLC6A3 | SLC6A3 3/4885SLC6A2 2/4885SLC6A4 5/4885 |
| US-20050020621-A1 | Tropane derivatives having dopamine reuptake inhibitor activity for the treatment of ischemic diseases | SLC6A2, SLC6A3, SLC18A2 | SLC6A3 2/4885SLC6A2 1/4885SLC6A4 5/4885 |
| US-20100178342-A1 | Solid Pharmaceutical Preparation | SLC6A2, SLC18A2, SLC6A3 | SLC6A3 3/4885SLC6A2 1/4885SLC6A4 6/4885 |
| US-20050203124-A1 | Compounds for the sustained reduction of body weight | SLC6A2, SLC6A3, SLC6A4 | SLC6A3 2/4885SLC6A2 1/4885SLC6A4 3/4885 |
| US-20100210626-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A MONOAMINE NEUROTRANSMITTER RE-UPTAKE INHIBITOR AND AN ACETYLCHOLINESTERASE INHIBITOR | SLC18A3, SLC6A2, SLC18A2 | SLC6A3 9/4885SLC6A2 2/4885SLC6A4 7/4885 |
| US-20050239824-A1 | Triple monoamine reuptake inhibitors for the treatment of chronic pain | SLC6A2, SLC6A4, HTR5A | SLC6A3 6/4885SLC6A2 1/4885SLC6A4 2/4885 |
| US-20050182090-A1 | Pharmaceutical composition comprising a monoamine neurotransmitter re-uptake inhibitor and a dopamine agonist | SLC6A2, SLC6A3, SLC18A2 | SLC6A3 2/4885SLC6A2 1/4885SLC6A4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.